Research programme: immunomodulators - Swecure

Drug Profile

Research programme: immunomodulators - Swecure

Alternative Names: Bacterial superantigens - Swecure; Staphylococcus aureus superantigen - Swecure; SWE 01; SWE 02; Swe01; Swe02

Latest Information Update: 15 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Swecure
  • Class Bacteria; Bacterial proteins
  • Mechanism of Action Immunostimulants; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity; Inflammatory bowel diseases

Most Recent Events

  • 01 Sep 2015 Swecure has patent protection for use of Swe 01 for the prevention of allergy in children in Europe and USA
  • 01 Sep 2015 Preclinical trials in Hypersensitivity (Prevention) in Sweden (unspecified route)
  • 01 Sep 2015 Preclinical trials in Inflammatory bowel disease in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top